Screening for Distress in Lung and Breast Cancer Outpatients: a Randomized Controlled Trial
Overview
Affiliations
Purpose: Distress has been recognized as the sixth vital sign in cancer care and several guidelines recommend routine screening. Despite this, screening for distress is rarely conducted and infrequently evaluated.
Methods: A program of routine online screening for distress was implemented for new patients with breast and lung cancer. Patients were randomly assigned to one of three conditions: (1) minimal screening: the distress thermometer (DT) only plus usual care; (2) full screening: DT, problem checklist, Psychological Screen for Cancer part C measuring anxiety and depression, a personalized report summarizing concerns and the report on the medical file; or (3) triage: full screening plus optional personalized phone triage with referral to resources. Patients in all conditions received an information packet and were reassessed 3 months later with the full screening battery.
Results: Five hundred eighty-five patients with breast cancer and 549 patients with lung cancer were assessed at baseline (89% of all patients), and 75.5% retained for follow-up. High prevalence of baseline distress was found across patients. Twenty percent fewer patients with lung cancer in triage continued to have high distress at follow-up compared to those in the other two groups, and patients with breast cancer in the full screening and triage conditions showed lower distress at follow-up than those in minimal screening. The best predictor of decreased anxiety and depression in full screening and triage conditions was receiving a referral to psychosocial services.
Conclusion: Routine online screening is feasible in a large cancer center and may help to reduce future distress levels, particularly when coupled with uptake of appropriate resources.
Cherny N, Nortje N, Kelly R, Zimmermann C, Jordan K, Kreye G ESMO Open. 2025; 10(1):104099.
PMID: 39765188 PMC: 11758828. DOI: 10.1016/j.esmoop.2024.104099.
Neuner J, Stolley M, Kamaraju S, Tiegs J, Sparapani R, Makris V Breast Cancer Res Treat. 2024; 209(3):541-552.
PMID: 39592520 DOI: 10.1007/s10549-024-07513-5.
Matsumoto Y, Umemura S, Okizaki A, Fujisawa D, Yamaguchi T, Oyamada S Cancer Med. 2024; 13(22):e70325.
PMID: 39556485 PMC: 11572738. DOI: 10.1002/cam4.70325.
Bourgognon F, Bechet D, Huin-Schohn C, Strelow A, Demarche L, Guillou M Front Psychol. 2024; 15:1409308.
PMID: 39021646 PMC: 11252038. DOI: 10.3389/fpsyg.2024.1409308.
Baik S, Clark K, Sanchez M, Loscalzo M, Celis A, Razavi M JMIR Cancer. 2024; 10:e49703.
PMID: 38986134 PMC: 11269963. DOI: 10.2196/49703.